Weight Gain While Switching from Polypharmacy to Ziprasidone: A Case Report.

نویسندگان

  • Chin-Pang Lee
  • Alice Pei-Jung Chen
  • Yeong-Yuh Juang
چکیده

Second-generation antipsychotics (SGAs), valproate, and sulpiride are related to significant weight gain and risk of metabolic syndrome (MetS). Among SGAs, olanzapine and clozapine are associated with the highest metabolic risk while ziprasidone is among one of the SGAs with the lowest risk. Several reports suggest that weight loss is observed in switching other antipsychotics to ziprasidone. Here we describe a female patient with chronic paranoid schizophrenia who had an unexpected weight gain and developed MetS during a cross-switch from a polypharmacy of olanzapine, valproate and sulpiride to ziprasidone monotherapy.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Patient choice as a driver of medication-switching in non-adherent individuals with bipolar disorder

OBJECTIVE Psychotropic-related weight gain is a common concern among patients with bipolar disorder (BD). This concern affects satisfaction with treatment and may lead to non-adherence and relapse. This was a 12-week, uncontrolled prospective trial of patient-choice-facilitated ziprasidone switching among non-adherent BD patients with weight concerns. This study was conducted from January 2011 ...

متن کامل

Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis

INTRODUCTION Antipsychotics (AP) induce weight gain. However, reviews and meta-analyses generally are restricted to second generation antipsychotics (SGA) and do not stratify for duration of AP use. It is hypothesised that patients gain more weight if duration of AP use is longer. METHOD A meta-analysis was conducted of clinical trials of AP that reported weight change. Outcome measures were ...

متن کامل

Ziprasidone alternative for olanzapine-induced hyperglycemia.

TO THE EDITOR: Among currently available atypical antipsychotic agents, clozapine and olanzapine are most often associated with clinically problematic weight gain and new-onset type 2 diabetes mellitus (1). Ziprasidone, a benzisothiazolylpiperazine, is a relatively new atypical antipsychotic that has been shown to be less likely to produce weight gain (2). We report on a patient with olanzapine...

متن کامل

Association of ADRA2A and MTHFR gene polymorphisms with weight loss following antipsychotic switching to aripiprazole or ziprasidone.

OBJECTIVES Various genetic polymorphisms have been reported to be associated with antipsychotic-induced weight gain. In this study, we aimed to determine whether risk polymorphisms in 12 candidate genes are associated with reduction in body mass index (BMI) of patients following switching of antipsychotics to aripiprazole or ziprasidone. METHODS We recruited 115 schizophrenia patients with me...

متن کامل

PM395. The Effectiveness of Cross-Tapering Switching to Ziprasidone in Patients with Schizophrenia or Schizoaffective Disorder

OBJECTIVE Switching antipsychotics is one useful therapeutic option when the treatment of schizophrenia encounters suboptimal efficacy and intolerability issues. This study aimed to investigate the efficacy and tolerability of cross-tapering switching to ziprasidone from other antipsychotics. METHODS A total of 67 patients with schizophrenia or schizoaffective disorder were recruited in this ...

متن کامل

ذخیره در منابع من

ذخیره در منابع من قبلا به منابع من ذحیره شده

{@ msg_add @}


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Clinical schizophrenia & related psychoses

دوره 9 3  شماره 

صفحات  -

تاریخ انتشار 2015